Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Understanding the role of progranulin in neurodevelopment and neurodevelopmental disorders
EF 2018-19
Résumé
There is a clear and pressing need to provide support for Canadians living with neurodevelopmental disorders like Fragile X Syndrome (FXS). FXS is the most common cause of heritable intellectual disability, affecting 1 in 4000 males and 1 in 6000 females in Canada. Beyond symptom management, there is currently no approved treatment for FXS. This is partly due to gaps in our understanding of the root causes of this syndrome. A clue was identified recently when it was demonstrated that mouse models of FXS have elevated levels of a protein called progranulin (GRN). Moreover, by reducing progranulin levels in these mice, some of the FXS symptoms were alleviated.
To further investigate the link between high levels of progranulin and FXS, we in the Leavitt lab have developed mice that express an excess of progranulin (GRN+ mice). We are characterizing the behaviour of these mice to see if they exhibit the same FXS-like symptoms as mouse models of FXS. Indeed, both GRN+ mice and FXS-like mice show hyperactivity, reduced social dominance, and abnormal repetitive behaviour engagement. To explore how increased progranulin has come to affect the behaviour of GRN+ mice, we will perform an in-depth characterization of their brains. In comparing the brains of GRN+ mice to those from FXS-like mice we will also gain insights into the extent of progranulin’s involvement in FXS.
Should increased progranulin expression be involved in causing FXS symptoms, this research will facilitate the development of therapeutics that treat FXS by reducing the levels of progranulin in the brain. Independent of determining the extent of progranulin’s role in FXS, this research is expected to improve the current understanding of how this enigmatic gene shapes the mammalian brain during development.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
415335
Name
Life Benjamin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding the role of progranulin in neurodevelopment and neurodevelopmental disorders
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autism; Behaviour Analysis; Fragile X Syndrome; Mouse Model; Neurodevelopmental Disorders
Abstract
There is a clear and pressing need to provide support for Canadians living with neurodevelopmental disorders like Fragile X Syndrome (FXS). FXS is the most common cause of heritable intellectual disability, affecting 1 in 4000 males and 1 in 6000 females in Canada. Beyond symptom management, there is currently no approved treatment for FXS. This is partly due to gaps in our understanding of the root causes of this syndrome. A clue was identified recently when it was demonstrated that mouse models of FXS have elevated levels of a protein called progranulin (GRN). Moreover, by reducing progranulin levels in these mice, some of the FXS symptoms were alleviated.
To further investigate the link between high levels of progranulin and FXS, we in the Leavitt lab have developed mice that express an excess of progranulin (GRN+ mice). We are characterizing the behaviour of these mice to see if they exhibit the same FXS-like symptoms as mouse models of FXS. Indeed, both GRN+ mice and FXS-like mice show hyperactivity, reduced social dominance, and abnormal repetitive behaviour engagement. To explore how increased progranulin has come to affect the behaviour of GRN+ mice, we will perform an in-depth characterization of their brains. In comparing the brains of GRN+ mice to those from FXS-like mice we will also gain insights into the extent of progranulin’s involvement in FXS.
Should increased progranulin expression be involved in causing FXS symptoms, this research will facilitate the development of therapeutics that treat FXS by reducing the levels of progranulin in the brain. Independent of determining the extent of progranulin’s role in FXS, this research is expected to improve the current understanding of how this enigmatic gene shapes the mammalian brain during development.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Life, Benjamin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~